- You can view the full Exact Sciences Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Venture Capital firm Benchmark reiterated its 'Buy' rating on the stock and $50 price target.
The secondary offering, to be underwritten by Jefferies, Bank of America/Merrill Lynch and Robert W. Baird, would offer 7 million shares.
Plus more from the biotechnology world on Wednesday, June 7.